RxDoctor Payments Data

Susan Buchbinder

Internal Medicine · San Francisco, CANPI 1629183066

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 90.0% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $3,564, 8.3 times the $429 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,273in general payments, 2019–2025

Across 19 payments — averaging $224.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4K
  • Gilead$429
$456,374in research payments, 2019–2025

Across 70 payments — averaging $6519.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$343K
  • GSK$66K
  • Gilead$48K

What the payments were for

  • Consulting fees$2,31854%
  • Travel & lodging$1,38933%
  • Food & beverage$56613%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck13$3,844
Gilead6$429

How this compares

$4,273 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →